Advertisement

Investigational New Drugs

, Volume 19, Issue 4, pp 327–328 | Cite as

Phase II Study of Pyrazoloacridine in Metastatic Renal Cell Carcinoma

  • J. Philip Kuebler
  • Gerald W. King
  • Pierre Triozzi
  • Timothy Moore
  • Eric H. Kraut
Article

Keywords

Public Health Carcinoma Cell Carcinoma Renal Cell Carcinoma Renal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCES

  1. 1.
    Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufman SH:Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.Clin Cancer Res 4:683–691,1998Google Scholar
  2. 2.
    Sebolt JS, Scavone SV, Pinter CD, Hamelehle KI, VonHoff DD, Jackson RC: Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.Cancer Res 47:4299–4304,1987Google Scholar
  3. 3.
    LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH: Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.Cancer Res50: 4900–4905,1990Google Scholar
  4. 4.
    Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic studies of Pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.J Clin Onc13:1975–1984,1995Google Scholar
  5. 5.
    National Cancer Institute: Investigator's Handbook: A manual for participants in clinical trials of investigational agents sponsored by DCTD, NCI.Bethesda, MD. National Cancer Institute,1993Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • J. Philip Kuebler
    • 1
  • Gerald W. King
    • 2
  • Pierre Triozzi
    • 3
  • Timothy Moore
    • 1
  • Eric H. Kraut
    • 3
  1. 1.Grant/Riverside HospitalColumbusU.S.A.
  2. 2.Cancer Center of the CarolinasGreenvilleU.S.A.
  3. 3.The James Cancer CenterColumbusU.S.A.

Personalised recommendations